Stocks › ABBV
AbbVie ABBV
US equityMarket cap rank #28
$291.31 +$3.07 (+1.07%)
Market closed · Nov 6, 8:10 pm ET · Last extended-hours $291.31 0.00%
Open$282.27
Prev close$288.24
Day range$281.07 – $291.73
Volume5.04M
Market cap$514.92B
P/E (TTM)50.1
Dividend yield2.34%
ABBV Stock News
Headlines matching AbbVie or the ABBV ticker, most recent first.
- News On Apogee Therapeutics Inc. (APGE) Now Under ABBV
- BMO Capital Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $300
- Scotiabank Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $280
- RBC Capital Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $280
- Scotiabank Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $280
- RBC Capital Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $280
- Erste Group Upgrades AbbVie(ABBV.US) to Buy Rating Positive
- Guggenheim Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $288 Positive
- AbbVie 2Q U.S. HUMIRA Rev $425M ABBV
- BofA Securities Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $282 Positive
- BofA Securities Upgrades AbbVie(ABBV.US) to Buy Rating, Raises Target Price to $282 Positive
- TD Cowen Initiates AbbVie(ABBV.US) With Buy Rating, Announces Target Price $280
- BMO Capital Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $300
- A Quick Look at Today's Ratings for AbbVie(ABBV.US), With a Forecast Between $280 to $300
- TD Cowen Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $280
No comments yet — be the first to weigh in on ABBV.
Sign in to join the discussion.